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We investigated whether circulating leucocytes from hypertensive patients exhibit more spontaneous, stimulated hydrogen peroxide (H 2 O 2 ) production and greater mitochondrial membrane potential (Dw) than those from normotensive individuals. We also investigated the effects of oral treatment with the angiotensin II (AT II) type 1 receptor blocker eprosartan (600 mg day
À1
) on these markers of oxidative stress. In 25 hypertensive patients and 28 healthy volunteers, spontaneous H 2 O 2 formation was measured by flow cytometry after preincubation of buffy coat-leucocytes from fresh peripheral venous blood at 37 1C with 2 0 ,7 0 dichlorofluorescein. Stimulation of H 2 O 2 formation by circulating leucocytes was elicited by the addition of tert-butylhydroperoxide (tBHP). Dw was determined by flow cytometry after the addition of tetramethylrhodamine methyl ester (TMRM). Compared with healthy individuals, lymphocytes from hypertensive patients exhibited higher Dw (12.28±3. 20 vs 
Introduction
Under physiological conditions, the rate and magnitude of oxidant formation in the cells is neutralized by the rate of oxidant elimination. However, when an excess of oxidants is generated, oxidative stress occurs with an accumulation of reactive oxygen species (ROS). ROS are biologically significant oxygen (O 2 ) derivatives whose importance is increasingly recognized through their modulating effects on the redox potential and thus on cell growth, apoptosis, migration, inflammation and the secretion of inflammatory cytokines. In hypertension, oxidative stress is a mediator of vascular injury and inflammation. In recent years, the role of oxidative stress in the pathogenesis and maintenance of hypertension has been established. Spontaneous activation, degranulation of circulating neutrophils and monocytes, has been shown in both animal models and clinical studies in patients with hereditary hypertension, demonstrating an association between oxidative stress and hypertension. [1] [2] [3] [4] Inflammatory pathways are already activated in the early stages of hypertension. 5 The mitochondrial electron transport chain is a permanent source of ROS in the cells, and mitochondria are considered to be the main producer of ROS. 6 Approximately 1-3% of total mitochondrial O 2 is partially reduced and leads to ROS production. 7 Through the transfer of one free electron to molecular O 2 , a superoxide anion (O 2 À ) is generated. This superoxide anion is scavenged by intramitochondrial superoxide dismutase leading to hydrogen peroxide (H 2 O 2 ) generation. 8 Mitochondria represent the main target of ROS, 9 which cause alterations to their membranes and associated damage of leucocytes. 10 The mitochondrial membrane potential (Dc) is increased in situations of oxidative stress. Among the three ROS (O 2 À , H 2 O 2 , hydroxyl radical (OH À )), H 2 O 2 is the most stable and has been chosen for the present study.
Angiotensin II (AT II) is a potent vasoconstrictor that plays a major role in the pathophysiology of hypertension through its biological effects, which include vasoconstriction, sodium retention and release of aldosterone. 11 Eprosartan mesylate (Teveten À , Solvay Healthcare Ltd, Southampton, UK) is a synthetic, orally active non-biphenyl nontetrazole AT II type 1 receptor blocker (ARB) that binds selectively to the AT type 1 (AT 1 ) receptor.
11
Eprosartan antagonizes the effects of AT II on blood pressure, renal blood flow and aldosterone secretion in healthy volunteers and achieves blood pressure control in hypertensive patients. 11 Recently, ARBs have been shown to confer benefits in addition to their ability to lower blood pressure, including anti-inflammatory and antioxidative effects within the vasculature. 12 The aim of this pilot study was to compare leucocytes in the peripheral blood of hypertensive patients with those of normotensive subjects in terms of Dc and H 2 O 2 generation. As hypertension is reversible, we also investigated whether alterations in leucocyte Dc and H 2 O 2 generation are corrected by treatment with the ARB eprosartan.
Materials and methods

Patients and controls
Twenty-five consecutive patients (nine females, 16 males; mean age 51.5±9.6 years) with World Health Organization stage 1 and 2 essential arterial hypertension (systolic blood pressure 140-179 mm Hg, diastolic blood pressure 90-109 mm Hg with no evidence of kidney, liver or heart involvement) for 9.9 ± 6.9 years were studied after a washout period of 2 weeks (baseline). Mean body mass index was 26.85 ± 3.85 kg m À2 . Three patients were obese (body mass index 430 kg m À2 ), while five had elevated cholesterol levels (mean 265.2±13.9 mg per 100 ml) and two were smokers. Two patients were diabetic, three were regular drinkers (o30 g alcohol per day) and no patients undertook regular strenuous physical exercise. None of the patients had a clinical history of cardiac or atherothrombotic disease but five patients had a family history of cardiac or atherothrombotic events.
The control group consisted of 28 healthy subjects who were matched for sex (12 females, 16 males), age (49.6±11.7 years) and risk factors and included the same proportions of smokers and hypercholesterolaemic and obese individuals as the treatment group. Individuals in the control arm were not receiving any medication and were studied in parallel to the patients.
This was a prospective, ex vivo, single-blind clinical trial in which the investigator measuring the cytometric parameters was not aware whether samples were from patients or controls. Patients were studied at baseline and 2 months after treatment initiation with eprosartan (600 mg day À1 as a single dose). Patients did not change their dietary habits or lifestyle during the study. All patients were included in the study after giving written informed consent. The study was performed according to the Declaration of Helsinki and with the approval of the Internal Review Board of La Fe University Hospital, Valencia, Spain.
Instruments
Routine biochemical parameters were determined using an OLYMPUS 5400 autoanalyzer (Mishima Olympus Co Ltd, Shizuoka-Ken, Japan). Haematological and haemostatic tests were performed using a Sysmex XE-2100 autoanalyzer (Sysmex Corporation, Kobe, Japan) and an ACL 9000 autoanalyzer (Instrumentation Laboratory, Lexington, MA, USA), respectively. Cytometric assays were carried out on an EPICS-XL-MCL flow cytometer (Beckman-Coulter, Miami, FL, USA). For standardization and alignment, the flow cytometer was calibrated daily with Immunocheck microbeads (Beckman-Coulter). Data acquisition was performed using System II software (Beckman-Coulter) and results are expressed as mean fluorescence intensity in arbitrary fluorescence units (AFU).
Leucocyte preparation
Blood was obtained from patients and healthy volunteers after 12 h of fasting and K3-ethylenediaminetetraacetic acid was added to prevent coagulation. Leucocytes were isolated by the Histopaque 1077 gravity technique. Blood (3 ml) was layered over 8 ml of Histopaque 1077 (Sigma-Aldrich, St Louis, MO, USA) in a 15-ml plastic tube. After 45-60 min of gravity sedimentation at room temperature, the leucocyte-rich plasma (upper layer) was removed and the agglutinated erythrocytes were discarded. White blood cells were diluted 1:0.5 v/v in RPMI-1640 culture medium (Gibco, Paisley, UK) supplemented with 10% foetal bovine serum (Gibco, Brooklyn, NY, USA), penicillin (100 U ml À1 ; Gibco), streptomycin (100 mg ml À1 ; Gibco) and 1 Â glutamine and were incubated for 30 min at 37 1C. The diluted leucocytes were counted in a Sysmex XE-2100 autoanalyzer and were adjusted to a concentration of 500 000 cells per ml with RPMI.
Assays
Mitochondrial membrane potential (Dc) and H 2 O 2 production were investigated by two cytometric fluorescence assays using the adequate created data acquisition protocols. In both assays, cells were identified according their morphology based on forward light scatter and side scatter properties. We can specifically analyse in separate lymphocytes, monocytes and granulocytes within the low forward light scatter and SS population. To identify granulocytes, CD3 þ /CD4 þ limphocytes, CD3À/CD4 þ monocytes, fluorochrome-conjugated monoclonal antibodies fluorescein isothiocyanate-CD3 (CD3-FITC), phycoerythrin-Texas red CD3 (CD3-ECD) and phycoerythrin cyanine 5 (CD4-PC5) (Immunotech, Marseille, France) were added.
In both assays, mean fluorescence intensity, measured in AFU, was used to quantify leucocyte responses.
Assay to determine mitochondrial membrane potential. The method for the measurement of Dc used, according to Huang et al.,
13 the cationiclipophilic indicator dye, tetramethylrhodamine methyl ester (TMRM; Fluka, Buchs, Switzerland), which binding to mitochondria in proportion to their membrane potentials. When used at low concentrations, TMRM does not suppress mitochondrial respiration.
14 To explain the method in detail, it consisted in: 200 ml aliquot of cells adjusted to 500 000 per ml in RPMI was incubated for 10 min at room temperature in the darkness with markers for CD3 (CD3-FITC, 10 ml) and CD4 (CD4-PC5, 5 ml) to enable identification of the different leucocyte populations. In a polystyrene tube, 50 ml of these labelled cells were collected and 950 ml of HEPES buffer (N-(2-hydroxyethyl) piperazine-N 0 -(2-ethanesulfonic acid)); Sigma-Aldrich, St Louis, MO, USA) was added. This tube was used as a labelling control. In another cytometer tube, 50 ml of the suspension of labelled cells were added as well as 950 ml of HEPES. TMRM was added to a final concentration of 500 nM and was incubated at 37 1C for 1 h. In this second tube, we first measured the mitochondrial membrane potential in granulocytes and monocytes, and secondly, the lymphocytes, using in each case the adequate created data acquisition protocols in the flow cytometer. Values were expressed in AFU.
Assay to measure mitochondrial H 2 O 2 production in stimulated and unstimulated cells. The assay to detect mitochondrial H 2 O 2 production was based on the use of 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA) (Sigma-Aldrich, MO, USA) oxidation. 15 This probe has low basal fluorescence but, when oxidized by H 2 O 2 , is converted into 2 0 ,7 0 -dichlorofluorescein (DCF) with a high fluorescent component at 520 nm. 16 In detail, the method consisted in: to a 150 ml aliquot of cells suspension (500 000 per ml) CD3.ECD (5 ml) and CD4.PC5 (5 ml) were added, and the suspension was incubated for 10 min at 37 1C in darkness. HEPES buffer (850 ml) was added and the blank values and label checking were measured in the cytometer. H 2 DCFDA was added to a final concentration of 20 mM and the suspension was incubated at 37 1C in darkness for 1 h (H 2 DCFDA is quickly photo-oxidized to fluorescent DCF by ultraviolet light and to a lesser degree by Blood pressure and heart rate in hypertensive patients receiving eprosartan treatment compared with normotensive subjects. *Po0.001 vs control group; **Po0.01 vs control group; ***Po0.05 vs baseline ns, not significant vs control group; NS, not significant vs baseline. BP, blood pressure; b.p.m., beats per minute; DBP, diastolic blood pressure; FU, follow-up; HR, heart rate; SBP, systolic blood pressure.
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. Fluorescence values were determined by flow cytometry after the blank values had been subtracted, and using the same, acquisition data protocols were created. To evaluate the production of H 2 O 2 in stimulated leucocytes and enable the comparison with spontaneous production in unstimulated cells, tert-butylhydroperoxide (tBHP) was employed and was added to suspensions to a final concentration of 2 mM. The tubes were incubated at 37 1C in darkness for 10 min and H 2 O 2 production was immediately measured by flow cytometry by means of the same acquisition data protocols. Values of H 2 O 2 production were expressed in AFU.
Data analysis
All data are expressed as mean ± s.d. of the mean. For statistical analysis, differences between treatment groups were assessed using a one-way analysis of variance test and correlations were identified with the two-tailed bivariate Pearson rank correlation coefficient. All analyses were calculated using the Statistical Package for Social Sciences (SPSS version 12.0) from Windows. A P-value of o0.05 was considered statistically significant.
Results
Blood pressure changes and safety considerations Data for systolic blood pressure, diastolic blood pressure and heart rate are shown in Figure 1 . Treatment with eprosartan for 2 months was associated with the normalization of blood pressure in hypertensive patients. Mean systolic blood pressure decreased from 151.5 ± 13.6 to 140.6 ± 12.5 mm Hg after 2 months of eprosartan treatment (Po0.05). The same tendency towards normalization was observed in diastolic blood pressure, which decreased from a mean value of 94.2 ± 9.8 to 86.7±11.5 mm Hg (Po0.05). No significant changes in heart rate were observed.
No serious adverse events were observed during follow-up. Only one patient discontinued treatment due to the presence of mild adverse events (headache and anxiety).
Routine analytical parameters Biochemical parameters. No statistically significant differences in biochemical parameters were found between patients at baseline, the same patients after 2 months of eprosartan treatment and healthy controls (data not shown). These parameters were glucose, creatinine, bilirubin, K, albumin, uric acid, total proteins, aspartate aminotransferase, alanine aminotransferase, g-glytamyl transpeptidase, alkaline phosphatase, triglycerides, Cl and Na. A non-significant trend towards decreased total cholesterol and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol was observed with eprosartan treatment (data not shown).
Haematological and haemostatic parameters. No statistically significant differences in haematological and haemostatic parameters were noted between the groups other than higher haematocrit and haemoglobin values in hypertensive patients, both at baseline and after 2-month eprosartan treatment, compared with individuals in the control arm (data not shown).
Cytometric analysis. Validation of techniques:
In previous tests, carried out at the conditions described in the present study, cells responded to positive controls such as H 2 O 2 incresing DCF fluorescence. They also responded when treated with p-trifluoromethoxycarbonyl cyanide phenyl hydrazone, decreasing TMRM fluorescence (data not shown). Regarding the method reproductibility, the intra-assay variation rates, obtained by means of five replications of the sample, are within 15.8% (for the production of H 2 O 2 by monocytes) and 10.3% (for the mitochondrial membrane potential by lymphocytes).
Mitochondrial membrane potential. At baseline, leucocytes from hypertensive patients showed significantly higher Dc compared with individuals in the control group (Table 1) . Treatment of patients with eprosartan for 2 months induced a significant decrease in the Dc of lymphocytes and granulocytes from hypertensive patients compared with baseline (reduced from 16.25 ± 2.88 to 10.89 ± 3.55 AFU and from 82.98±17.18 to 56.18±29.34 AFU, respectively). No statistically significant changes from baseline were observed in the Dc of Table 2 shows levels of mitochondrial H 2 O 2 in unstimulated leucocytes from hypertensive patients at baseline and after 2 months of eprosartan treatment compared with normotensive individuals. Spontaneous mitochondrial H 2 O 2 production was greater in unstimulated lymphocytes from hypertensive patients at baseline than in healthy controls (8.98 ± 9.97 vs 4.75 ± 5.15 AFU, respectively; Po0.05). No significant differences in H 2 O 2 levels were observed between hypertensive and normotensive individuals in terms of either unstimulated monocytes or unstimulated granulocytes. Granulocyte H 2 O 2 production was significantly lower after 2 months of eprosartan treatment (2.21 ± 4.13 vs 6.45 ± 3.58 AFU, respectively; Po0.01). Data suggested that eprosartan treatment was associated with a decrease in the spontaneous production of ROS by lymphocytes and monocytes but this decrease was not statistically significant.
Oxidative stress, inflammation and arterial hypertension contribute to a self-perpetuating cycle of disease. The effects of eprosartan on these processes could enable the interruption of this cycle. Thus, eprosartan shows potential in the treatment of hypertensive patients.
H 2 O 2 production in stimulated leucocytes. H 2 O 2 production by tBHP-stimulated cells from hypertensive patients, before and after eprosartan treatment, and from normotensive controls are shown in Table 3 Correlations. Statistically significant correlations (Pearson's correlation coefficient) were found between several of the studied parameters. The most significant correlations (P ¼ 0.000) are shown in Table 4 . Using the Pearson's correlation coefficient test of significance, two tailed (SPSS version 12.0), we did not find any numeric correlation between mitochondrial oxidative stress and arterial pressure at baseline after treatment with eprosartan (data not shown). Table 4a shows the correlations between the three leucocyte populations in terms of spontaneous H 2 O 2 production. Significant correlations were observed, with the greatest correlation occurring between granulocytes and lymphocytes (r ¼ 0.8846). Table 4b shows the correlations between the three 
Discussion
This study has demonstrated that the lymphocytes from hypertensive patients exhibit higher mitochondrial membrane potential and greater spontaneous H 2 O 2 production than those from healthy individuals.
The relationship between leucocyte oxidative stress and hypertension has been demonstrated. 5, 16 In this study, we provide evidence that increased H 2 O 2 production after leucocyte stimulation by tBHP is greater in hypertensive patients than in normotensive controls. In addition, H 2 O 2 production by unstimulated lymphocytes is also increased in these patients. The increased production of H 2 O 2 by leucocytes could result in oxidative injury, which has been implicated in the pathophysiology of hypertension, inflammation and atherosclerosis. 17, 18 This phenomenon could contribute to systemic oxidative stress, inflammation and cardiovascular and renal complications in hypertensive patients. However, some researchers have proposed that oxidative stress is not increased in mild-to-moderate hypertension, 19 suggesting that ROS may be critical in severe hypertension but not in the early stages of the disease.
In this investigation, H 2 O 2 levels were studied because it is one of the most stable of the ROS. Our results indicate that, using flow cytometry, H 2 It has been reported that hypertensive patients exhibit greater plasma concentrations of H 2 O 2 than healthy individuals, which could represent a causative factor in the vascular and organ damage associated with hypertension. 21 In this study, we found that lymphocytes from hypertensive patients spontaneously produced H 2 O 2 to a higher degree than normotensive individuals and that the administration of eprosartan decreased this spontaneous production. This effect of eprosartan on leucocyte dysfunction suggests that the increased levels of H 2 O 2 production in hypertensive patients may be reversible.
It has been assumed that mature human granulocytes have few functional mitochondria. 22 However, evidence is now emerging to suggest that mitochondrial function may play a role in leucocyte metabolism and apoptosis. 23 Data from the present study show that granulocytes from patients with uncontrolled hypertension have higher mitochondrial membrane potentials than those of normotensive subjects. This abnormality can be corrected by 2 months of treatment with eprosartan. Conversely, eprosartan has little effect on monocyte mitochondrial membrane potential; however, it is unlikely that this is of any clinical significance due to the low circulating populations of monocytes in the peripheral blood.
The presence of AT II receptors has been demonstrated on leucocytes. 24, 25 These receptors seem to play a role in the activation and adhesion of monocytes and polymorphonuclear leucocytes. 26 In a previous study, our group showed that hypertensive patients exhibit greater platelet activation than normotensive individuals. With eprosartan treatment, such activation can be controlled, probably through a mechanism acting on cytosolic calcium kinetics. 27 It is currently accepted that platelets and their products can influence leucocyte function in whole blood under physiological conditions. 28 Similarly, platelet activation may be influenced by leucocytes. 29 Given that AT II-induced changes in cytosolic calcium in peripheral leucocytes can be modulated by ARBs 30 and that intracellular ionized calcium is a key mediator in leucocyte activation and ROS production, 31 we speculate that eprosartan could exert its effects on ROS generation in hypertensive patients through this mechanism. However, other mechanisms could also be involved, such as decreased antioxidant activity for example, superoxide dismutases and catalase activity) and reduced levels of ROS scavengers (for example, glutathione and vitamin E), which may also contribute to oxidative stress. 32 Other authors show that patients with hypertension show an enhanced oxidative stress with formation of O 2 À in platelets that was not dependent on blood pressure but could be mediated by AT1 receptors through NADPH oxidase activation probably, because patients treated with ARB irbesartan showed a decrease in platelet O 2 À production. 33 Our results are coherent with this observation as our hypertensive patients also showed an enhanced oxidative stress in leucocytes. As leucocytes have receptors type 1 on their membrane, the effect of eprosartan upon the oxidative stress could be attributable to the blockage of these receptors of AT II. However, we agree that due to AT II induce O 2 À formation in cells such as vascular endothelial cells, ARB antihypertensive drugs could act as 'antioxidants' according to Zhang et al., 34 reducing the oxidative stress in other kind of cells such as leucocites. According to the authors, 34 our results could be considered, to some extent, as a consequence of the 'causative antioxidant' benefits of eprosartan. Further studies are required to explore the beneficial effects of eprosartan and the mechanisms by which hypertension promotes the activation of peripheral blood leucocytes.
